



Telix Pharmaceuticals Limited
ACN 616 620 369
Suite 401, 55 Flemington Road
North Melbourne
Victoria, 3051
Australia

ASX RELEASE

Telix Pharmaceuticals 5th Annual General Meeting of Shareholders **Results of Meeting**

Melbourne (Australia) – 18 May 2022. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to advise that each of the resolutions put to the Annual General Meeting was passed.

All resolutions were determined by Poll.

The results provided in the attached document are provided in accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on [Twitter](https://twitter.com/TelixPharma) (@TelixPharma) and [LinkedIn](https://www.linkedin.com/company/telix-pharmaceuticals).

Telix's lead product, Illuccix[®] (kit for preparation of gallium-68 (⁶⁸Ga) gozetotide (also known as ⁶⁸Ga PSMA-11) injection) for prostate cancer imaging, has been approved by the U.S. Food and Drug Administration (FDA),¹ and by the Australian Therapeutic Goods Administration (TGA).² Telix is also progressing marketing authorisation applications for this investigational candidate in Europe³ and Canada.⁴

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Corporate Communications and Investor Relations
Email: kyahn.williamson@telixpharma.com

¹ ASX disclosure 20 December 2021.

² ASX disclosure 2 November 2021.

³ ASX disclosure 10 December 2021.

⁴ ASX disclosure 16 December 2020.

This announcement has been authorised for release by the Company Secretary.

Legal Notices

This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions.

The Telix Pharmaceuticals name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved).

ANNUAL GENERAL MEETING
Wednesday, 18 May, 2022

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Total votes cast in the poll (where applicable)			
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	Abstain **	Result
1	ADOPTION OF THE REMUNERATION REPORT	N	92,153,028 98.97%	177,607 0.19%	779,682 0.84%	474,279	101,353,899 99.82%	179,427 0.18%	484,279	Carried
2	RE-ELECTION OF MS JANN SKINNER AS DIRECTOR	NA	93,529,079 98.78%	369,783 0.39%	785,554 0.83%	50,180	153,775,570 99.76%	371,603 0.24%	50,180	Carried
3	ELECTION OF MS TIFFANY OLSON AS DIRECTOR	NA	93,710,953 98.98%	185,580 0.20%	784,893 0.83%	53,170	153,958,603 99.88%	185,580 0.12%	53,170	Carried
4	ADOPTION OF TELIX EQUITY INCENTIVE PLAN	NA	86,758,313 95.21%	3,585,413 3.93%	780,041 0.86%	439,418	95,968,543 96.41%	3,578,233 3.59%	449,418	Carried
5	APPROVAL OF ISSUE OF MANAGING DIRECTOR SARS TO DR CHRISTIAN BEHRENBRUCH	NA	88,769,803 94.91%	3,993,009 4.27%	764,029 0.82%	57,755	98,374,021 96.11%	3,985,829 3.89%	57,755	Carried
6	APPROVAL OF ISSUE OF NON-EXECUTIVE DIRECTOR SARS TO MS TIFFANY OLSON	NA	77,196,558 82.58%	15,518,225 16.60%	764,029 0.82%	105,784	86,800,776 84.84%	15,511,045 15.16%	105,784	Carried
7	APPROVAL OF ISSUE OF SHARES UNDER THE PLACEMENT	NA	20,796,079 95.85%	135,732 0.63%	764,029 3.52%	1,177,515	53,079,033 99.76%	128,552 0.24%	28,733,765	Carried
8	APPROVAL OF ISSUE OF EMPLOYEE SARS TO PARTICIPATING EMPLOYEES	NA	87,289,055 95.43%	3,396,271 3.71%	780,256 0.85%	97,603	96,499,500 96.60%	3,399,091 3.40%	97,603	Carried
9	APPROVAL OF AMENDMENTS TO THE CONSTITUTION	NA	81,753,244 86.32%	11,459,893 12.10%	1,492,656 1.58%	28,803	142,696,837 92.56%	11,461,713 7.44%	38,803	Carried

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item